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S U M M A R Y
Objectives: To determine risk factors for poor outcomes among patients with pulmonary multidrug- or
extensively drug-resistant (M/XDR) tuberculosis (TB) in Georgia.
Methods: This was a prospective, population-based observational cohort study.
Results: Among 380 M/XDR-TB patients (mean age 38 years), 179 (47%) had a poor outcome: 59 (16%)
died, 37 (10%) failed, and 83 (22%) defaulted. Newly diagnosed M/XDR-TB cases were signiﬁcantly more
likely to have a favorable outcome than retreatment cases (odds ratio (OR) 4.26, 95% conﬁdence interval
(CI) 1.99–9.10, p < 0.001). In the multivariable analysis, independent risk factors for a poor treatment
outcome included previous treatment history (OR 2.92, 95% CI 1.29–6.58), bilateral disease (OR 1.90, 95%
CI 1.20–3.01), body mass index (BMI, kg/m2) 18.5 (OR 1.91, 95% CI 1.11–3.29), and XDR-TB (OR 2.28,
95% CI 1.11–4.71). Patients who underwent surgical resection (OR 0.27, 95% CI 0.11–0.64) and had
sputum culture conversion by 4 months (OR 0.33, 95% CI 0.21–0.52) were signiﬁcantly less likely to have
poor treatment outcomes.
Conclusions: Adjunctive surgery appeared to be beneﬁcial in treating patients with M/XDR-TB.
Retreatment cases, XDR-TB, bilateral disease, and low BMI were associated with a poor outcome.
Additional studies are needed to further deﬁne the apparent beneﬁcial role of surgery in the treatment of
M/XDR-TB.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Multidrug-resistant (MDR) and extensively drug-resistant
(XDR) tuberculosis (TB) have emerged as serious public health
problems in many countries, including Georgia, and threaten to
undermine efforts to improve TB control.1 MDR-TB is deﬁned as
Mycobacterium tuberculosis resistant to both isoniazid and
rifampin, and as XDR by additional resistance to any ﬂuoroquino-
lone and any one of three injectable agents: amikacin, capreo-
mycin, and kanamycin. Two meta-analyses reported the average
proportion of successful treatment outcomes in MDR-TB patients
to be 62%, while in XDR patients it was only 42%.2,3 Principal
reasons for poor outcomes with M/XDR-TB include lengthy,
costly, and inadequate treatment regimens and limited availabil-
ity of second-line drugs (SLDs). In 2008, it was estimated that of
the approximately 440 000 MDR-TB cases worldwide, less than 2%
were treated with a World Health Organization (WHO) recom-
mended regimen.4 In an effort to improve SLD access, the Green* Corresponding author. Tel.: +995 593 479506; fax: +995 32 2910751.
E-mail address: mgegia@gmail.com (M. Gegia).
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important progress in expanding access to quality-assured SLDs
for M/XDR-TB patients treated within a programmatic setting. To
date, more than 29 000 patients have received or are receiving
care for M/XDR-TB through the Green Light Committee, with the
estimated number of patients on treatment expected to double in
the next year.5
Georgia is one of 27 high MDR-TB burden countries as
designated by the WHO.6 A 2006 population-based survey carried
out by our group found 7% of all new TB cases and 27% of
retreatment cases were either MDR- or XDR-TB.7 Of particular
concern is that more recent in-country surveillance data have
shown the prevalence of M/XDR-TB to be >10% in newly diagnosed
cases and >40% in retreatment cases. The ﬁrst pilot MDR-TB
treatment program in Georgia took place in 2006 in collaboration
with Me´decins San Frontie`res. Based on the success of this project
and the rising prevalence of M/XDR-TB, the Georgian National TB
Program (NTP) applied for and received Green Light Committee
Initiative approval for quality-assured SLD access. The approval
from the Green Light Committee in combination with support from
The Global Fund enabled universal access to diagnosis and
treatment for M/XDR-TB in Georgia beginning in 2008.ses. Published by Elsevier Ltd. All rights reserved.
M. Gegia et al. / International Journal of Infectious Diseases 16 (2012) e391–e396e392The main objective of this study was to assess the clinical
outcomes of the ﬁrst cohort of M/XDR-TB patients treated with
SLDs by the Georgian NTP and to determine risk factors for poor
treatment outcome.
2. Methods
2.1. Study population
All patients in Georgia aged 16 years with laboratory-
conﬁrmed pulmonary M/XDR-TB initiating treatment between
March and December 2008 through the Georgian NTP were
enrolled in a prospective observational study. The study was
approved by the institutional review boards of the Georgian
National Center for Tuberculosis and Lung Diseases, Georgia, and
Emory University, USA.
2.2. Drug susceptibility testing
All patients had sputum culture and ﬁrst- and second-line drug
susceptibility testing (DST) performed at the National TB Reference
Laboratory in Tbilisi, Georgia. DST to ﬁrst-line drugs was
performed using the absolute concentration method on Lo¨w-
enstein–Jensen medium with the following drug concentrations:
streptomycin 4 mg/ml, isoniazid 0.2 mg/ml, rifampin 40 mg/ml,
and ethambutol 2 mg/ml. DST to second-line anti-TB drugs was
performed using the proportion concentration method with the
following drug concentrations: ethionamide 40.0 mg/ml, oﬂoxacin
2.0 mg/ml, para-aminosalicylic acid 0.5 mg/ml, capreomycin
40.0 mg/ml, and kanamycin 30.0 mg/ml.8 Pyrazinamide testing
was performed using the MGIT960 liquid broth system (concen-
tration 100 mg/ml).9 External quality control of the Georgian
National TB Reference Laboratory was performed by the WHO-
afﬁliated Supranational Reference Laboratory in Antwerp,
Belgium.8
2.3. Deﬁnitions
Treatment outcomes were deﬁned using WHO criteria.10 Cure
and treatment completion were classiﬁed as a favorable outcome;
treatment failure, death during treatment, and default were
classiﬁed as a poor outcome.10
2.4. Treatment
Treatment regimens were individualized based on DST results
and guided by WHO recommendations.10 Regimens were designed
to include at least four drugs to which the patient’s M. tuberculosis
isolate was susceptible.10 All treatment regimens included a
ﬂuoroquinolone (moxiﬂoxacin or levoﬂoxacin) and also an
injectable agent (i.e., kanamycin or capreomycin) for at least 6
months. Treatment was continued for at least 18 months after
achieving a negative sputum culture. All patients received
treatment through directly observed therapy (DOT). Most patients
received initial care as an inpatient before transitioning to
outpatient treatment.
The decision to perform surgical resection (i.e., adjunctive
surgical therapy) was made by the Georgian NTP Drug Resistance
Committee. In addition, sufﬁcient pulmonary function to tolerate
resection and a localized lesion amenable to resection were
required.
2.5. Data collection
Demographic and clinical information were collected from the
medical records. Sputum culture and DST results were obtainedfrom either the medical records or the National TB Reference
Laboratory database. Treatment outcomes were collected as part of
ongoing surveillance at the NTP using a standardized ‘treatment
outcomes’ form.
2.6. Statistical analysis
Data analyses were performed using SAS software, version 9.1
(Cary, NC, USA). For descriptive statistics, differences in categorical
variables were tested using the Chi-square test, and for continuous
variables a two-sample t-test was used. A binary multivariable
logistic regression model was used to evaluate the independent
association of potential risk factors with poor outcome. Model
building and selection was based on the purposeful selection of
covariates strategy as previously described, based on epidemio-
logical ﬁndings in the bivariate analysis and biological plausibili-
ty.11 A p-value of <0.05 was considered signiﬁcant.
3. Results
3.1. Patient characteristics
Three hundred and eighty patients in Georgia with laboratory-
conﬁrmed pulmonary M/XDR-TB were enrolled in the study. The
average age was 38 years (range 16–81 years), and 109 patients
(29%) were female (Table 1). Among the 380 patients with M/XDR-
TB, 334 (88%) had a prior history of TB treatment (‘retreatment
cases’) and 46 (12%) were newly diagnosed TB cases (Table 1).
Compared to new cases, retreatment cases were signiﬁcantly older,
reported alcohol abuse more frequently, and were more likely to
have bilateral radiological disease (Table 1). In addition, newly
diagnosed M/XDR-TB cases had a higher rate of culture conversion
at 4 months than retreatment cases (67% vs. 43%, p = 0.002). There
was no signiﬁcant difference in the rate of XDR-TB among new and
retreatment cases (9% vs. 13%, p = 0.36).
3.2. Drug resistance
Based on DST, the average number of drugs to which M.
tuberculosis isolates were resistant was 5.4 (range 2–10). In
addition to isoniazid and rifampin resistance (100% by deﬁnition),
there were high rates of drug resistance to streptomycin (92%),
ethambutol (66%), and ethionamide (59%), while the proportion of
patients resistant to the remainder of drugs tested by DST was
lower (Table 2). Resistance to pyrazinamide was 22%. Patients who
had a history of receiving treatment with SLDs had signiﬁcantly
higher rates of resistance to ﬂuoroquinolones (oﬂoxacin, 41% vs.
17%, p < 0.001), kanamycin (51% vs. 35%, p = 0.002), and capreo-
mycin (38% vs. 20%, p < 0.001) compared to newly diagnosed TB
cases.
3.3. Treatment outcomes
Among 380 patients with M/XDR-TB, 201 (53%) had a favorable
outcome and 179 (47%) had a poor treatment outcome, including
59 (16%) who died, 37 (10%) with treatment failure, and 83 (22%)
who defaulted from treatment (Table 3). Newly diagnosed M/XDR-
TB cases were signiﬁcantly more likely to have a favorable outcome
than retreatment cases (37/46 (80%) vs. 164/334 (49%); odds ratio
(OR) 4.26, 95% conﬁdence interval (CI) 1.99–9.10; p < 0.001).
3.4. Prognostic factors for a poor outcome
In univariable analysis, factors that were associated with a poor
treatment outcome included older age, body mass index (BMI, kg/
m2) 18.5, bilateral disease on chest radiograph, being a
Table 1
Clinical characteristics of 380 patients with multidrug- or extensively drug-resistant tuberculosis (M/XDR-TB)
Patient characteristics Number of patients, n (%)
(N = 380)
New cases, n (%)
(n = 46)
Retreatment cases, n (%)
(n = 334)
p-Valuea
Female sex 109 (29) 21 (46) 88 (26) 0.007
Age (years), mean (range) 38 (16–81) 33 (16–81) 39 (16–77) 0.004b
Married 258 (68) 29 (63) 229 (69) 0.45
Employed 52 (14) 10 (22) 42 (13) 0.09
Current smoker 152 (40) 14 (30) 138 (41) 0.16
Alcohol use 94 (25) 6 (13) 88 (26) 0.05
History of injection drug use 14 (4) 0 14 (4) 0.16
History of incarceration 51 (13) 4 (9) 47 (14) 0.31
Diabetes mellitus 35 (9) 4 (9) 31 (9) 0.90
HIV infection 5 (1) 1 (2) 4 (1) 0.52
BMI 18.5 kg/m2 92 (24) 8 (17) 84 (25) 0.25
Bilateral lesions on X-ray 198 (52) 17 (37) 181 (54) 0.02
Drug resistance pattern: XDR 49 (13) 4 (9) 45 (13) 0.36
Treatment characteristics
4-month culture conversion 173 (46) 31 (67) 142 (43) 0.002
Adjunctive surgical resection 37 (10) 5 (11) 32 (10) 0.78
XDR, extensively drug-resistant; BMI, body mass index.
a p-Value for Chi-square test unless otherwise stated.
b p-Value for two-sided, unpaired t-test.
Table 2
Drug resistance at start of treatment by patient category (N = 380)
New cases, n (%) Prior ﬁrst-line anti-TB drug treatment, n (%) Prior second-line anti-TB drug treatment, n (%) Total, n (%)
First-line drugs
Isoniazid 46 (100) 253 (100) 81 (100) 380 (100)
Rifampin 46 (100) 253 (100) 81 (100) 380 (100)
Streptomycin 39 (85) 235 (93) 74 (91) 348 (92)
Ethambutol 28 (61) 171 (68) 53 (65) 252 (66)
Pyrazinamide 14 (30) 57 (23) 14 (17) 85 (22)
Second-line drugs
Oﬂoxacin 8 (17) 43 (17) 33 (41) 84 (22)
Kanamycin 16 (35) 80 (32) 41 (51) 137 (36)
Capreomycin 9 (20) 49 (19) 31 (38) 89 (23)
Ethionamide 24 (52) 150 (59) 51 (63) 225 (59)
Cycloserine 2 (4) 10 (4) 5 (6) 17 (4)
PAS 7 (15) 39 (15) 12 (15) 58 (15)
TB, tuberculosis; PAS, para-aminosalicylic acid.
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gender, having had adjunctive surgical therapy, and sputum
culture conversion at 4 months were all associated with better
outcomes (i.e., a reduced risk of a poor outcome) (Table 4).
In multivariable analysis, factors that were independently
associated with a poor treatment outcome included BMI 18.5,
bilateral pulmonary disease on chest radiograph, being a
retreatment case, and the presence of XDR-TB (Table 4). In the
multivariable analysis, sputum culture conversion to negative for
M. tuberculosis by 4 months (OR 0.33, 95% CI 0.21–0.52) and
having had an adjunctive surgical resection (OR 0.27, 95% CI
0.11–0.64) were associated with a reduced risk of a poor outcomeTable 3
Treatment outcomes of 380 multidrug- or extensively drug-resistant tuberculosis (M/X
New cases, n (%)
(n = 46)
Prior ﬁrst-line treatme
(n = 253)
Favorable outcome 37 (80) 133 (53) 
Cure 27 (59) 101 (40) 
Completed 10 (22) 32 (13) 
Poor outcome 9 (20) 120 (47) 
Death 2 (4) 33 (13) 
Failure 2 (4) 19 (8) 
Default 5 (11) 68 (27) (i.e., associated with a more favorable treatment outcome)
(Table 4).
Two additional multivariable logistic models were run to
further explore the relationship of prior TB treatment and drug
resistance with poor outcomes (Table 5). Compared to patients
with MDR-TB, patients with MDR-TB plus ﬂuoroquinolone
resistance (OR 4.41, 95% CI 1.82–10.70) or XDR-TB (OR 3.02,
95% CI 1.37–6.64) were signiﬁcantly more likely to have a poor
treatment outcome. In the second alternative model, increasing
total drug resistance was associated with an increasing likelihood
of a poor outcome. In both alternative models, prior treatments
were signiﬁcantly associated with poor outcomes.DR-TB) patients by patient category
nt, n (%) Prior second-line treatment, n (%)
(n = 81)
Total, n (%)
(N = 380)
31 (38) 201 (53)
25 (31) 153 (40)
6 (7) 48 (13)
50 (62) 179 (47)
24 (30) 59 (16)
16 (20) 37 (10)
10 (12) 83 (22)
Table 5
Alternative logistic multivariable regression models for poor outcomes among 380
multidrug- or extensively drug-resistant tuberculosis (M/XDR-TB) patients
Adjusted OR (95% CI) p-Value
Alternative model 1
Age 1.02 (1.00–1.04) 0.06
BMI 18.5 kg/m2 1.96 (1.12–3.44) 0.02
Bilateral X-ray lesions 1.89 (1.18–3.02) 0.008
Adjunctive surgery 0.24 (0.10–0.60) 0.002
4-month culture conversion 0.34 (0.21–0.55) <0.001
Drug resistance pattern
MDR 1.00
MDR + FQ resistance 4.41 (1.82–10.70) 0.001
MDR + AG resistance 1.64 (0.94–2.86) 0.08
XDR 3.02 (1.37–6.64) 0.006
Treatment category
New 1.00
Prior ﬁrst-line treatment 2.92 (1.27–6.76) 0.01
Prior second-line treatment 3.37 (1.30–8.73) 0.01
Alternative model 2
Age 1.02 (1.00–1.03) 0.10
BMI 18.5 kg/m2 1.92 (1.10–3.37) 0.02
Bilateral X-ray lesions 1.94 (1.22–3.10) 0.006
Adjunctive surgery 0.29 (0.12–0.68) 0.005
4-month culture conversion 0.31 (0.19–0.49) <0.001
Total number of resistant drugs
0–3 1.00
4–6 2.77 (1.36–5.67) 0.005
7 3.71 (1.68–8.21) 0.001
Treatment category
New 1.00
Prior ﬁrst-line treatment 2.80 (1.21–6.48) 0.005
Prior second-line treatment 3.87 (1.52–9.88) 0.001
OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; MDR, multidrug-
resistant; FQ, ﬂuoroquinolone; AG, aminoglycoside; XDR, extensively drug-
resistant.
Table 4
Predictors of poor outcome among patients with multidrug- or extensively drug-resistant tuberculosis (M/XDR-TB)
Variable Favorable outcome (n = 201) Poor outcome (n = 179) Univariable analysis Multivariable analysis
OR (95% CI) p-Valuea OR (95% CI) p-Value
Age, years, mean 36.6 40.3 1.02 (1.01–1.04) 0.003 1.01 (1.00–1.03) 0.16
Female sex 68 (34) 41 (23) 0.58 (0.37–0.92) 0.02 - -
Married 129 (64) 129 (72) 1.44 (0.93–2.23) 0.10 - -
Employed 34 (17) 18 (10) 0.55 (0.30–1.01) 0.06 - -
Current smoker 79 (39) 73 (41) 1.06 (0.71–1.60) 0.77 - -
Alcohol use 43 (21) 51 (28) 1.42 (0.89–2.30) 0.16 - -
IDU 5 (2) 9 (5) 1.99 (0.65–6.07) 0.23 - -
Prison history 23 (11) 28 (16) 1.44 (0.79–2.60) 0.23 - -
Diabetes 19 (9) 16 (9) 0.94 (0.47–1.89) 0.86 - -
HIV 3 (1) 2 (1) 0.75 (0.12–4.56) 0.75 - -
BMI 18.5 kg/m2 34 (17) 58 (32) 2.35 (1.45–3.82) 0.001 1.91 (1.11–3.29) 0.02
X-ray ﬁndings
Bilateral disease 86 (43) 112 (63) 2.24 (1.48–3.38) <0.001 1.90 (1.20–3.01) 0.006
Treatment category
New 37 (18) 9 (5) 1.00 - -
Prior ﬁrst-line 133 (66) 120 (67) 3.71 (1.72–8.00) <0.001 - -
Prior ﬁrst- and second-line 31 (15) 50 (28) 6.63 (2.82–15.59) <0.001 - -
All retreatment cases 164 (82) 170 (95) 4.26 (1.99–9.10) <0.001 2.92 (1.29–6.58) <0.001
Drug resistance categories
XDR 17 (8) 32 (18) 2.36 (1.26–4.41) <0.001 2.28 (1.11–4.71) 0.03
Non-XDR 184 (92) 147 (82)
Adjunctive surgery 29 (14) 8 (4) 0.28 (0.12–0.62) 0.002 0.27 (0.11–0.64) 0.003
4-month culture conversion 120 (60) 53 (30) 0.28 (0.19–0.44) <0.001 0.33 (0.21–0.52) <0.001
OR, odds ratio; CI, conﬁdence interval; IDU, injection drug use; BMI, body mass index; XDR, extensively drug-resistant.
a p-Value for Chi-square test unless otherwise stated.
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Georgia is one of only a few low- and middle-income countries
that has had a rapid scale-up of treatment for M/XDR-TB. In less than
2 years, Georgia has achieved universal access to diagnosis and
treatment of M/XDR-TB. This current study examined treatment
outcomes among the ﬁrst cohort of patients with pulmonaryM/XDR-TB to undergo treatment in the country of Georgia.10 The
large majority (88%) of patients in this cohort were retreatment
cases, likely reﬂecting the large pool of patients with chronic TB in
Georgia who did not have access to diagnosis and treatment of M/
XDR-TB until 2008. The overall proportion of favorable treatment
outcomes in our study was similar to previously published
studies,12,13 but somewhat lower than that reported in a recent
meta-analysis, which estimated an average successful outcome
proportion for MDR-TB of 62% (95% CI 58–67%).2 Some differences
that may have accounted for a lower success rate in Georgia were the
high proportion of retreatment cases and a relatively high treatment
default rate (22%). Retreatment cases were older, more likely to have
bilateral disease, had increasing drug resistance, and many had
chronic TB disease for which they received multiple treatment
regimens prior to the availability of diagnosis and treatment of M/
XDR-TB in Georgia. Retreatment may be a surrogate marker for more
severe disease, and these patients may be less responsive to
treatment. Other studies have similarly found a higher proportion of
poor outcomes in retreatment cases.14–17 This ﬁnding emphasizes
both the importance of proper detection of M/XDR-TB and access to
quality-assured SLDs.
XDR-TB was an independent risk factor for a poor treatment
outcome in our study, a ﬁnding that has been noted in previous
studies.18,19 The treatment success rate among those with XDR-TB
(35%) in our study was in the lower range of that previously
reported – 32% to 55%.3 In our study, the presence of ﬂuoroquino-
lone resistance was an independent risk factor associated with a
poor treatment outcome and highlights the need for new agents
that can be employed in the treatment of M/XDR-TB.
A relatively high prevalence (13%) of XDR-TB was found among
patients with MDR-TB in Georgia. XDR-TB emerged at a time when
SLDs were not available through the Georgian NTP. In Georgia, SLDs
including the ﬂuoroquinolones and injectable drugs were, and still
are, available in pharmacies for over-the-counter purchase.20 We
suspect that their inappropriate use under non-program conditions
has led to the development of XDR-TB in Georgia.
In our study, the default rate (22%) was relatively high. This
ﬁnding is concerning because patients defaulting therapy have
been found to have high rates of subsequent mortality and pose a
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high level of treatment interruption occurred despite all patients
receiving intensive case management, including psychological
evaluation and care and DOT. Further investigations into the
reasons for patient default and efforts to improve patient
adherence, especially among retreatment patients, should improve
overall M/XDR-TB treatment outcomes in Georgia and are
important to enhance TB control efforts in Georgia.
In our study, independent risk factors for poor treatment
outcomes also included low BMI (18.5). Low BMI has been shown
to be associated with an increased risk of TB and also worse
outcomes in MDR-TB patients.14,22 Our data are consistent with
previous studies that have emphasized the importance of
nutritional support for M/XDR-TB patients. Additional indepen-
dent risk factors found to be signiﬁcantly associated with favorable
treatment outcomes included adjunctive surgical therapy and
sputum culture conversion at 4 months. Our study suggests that
surgical resection may be an important adjunctive measure in
enhancing treatment cure among patients with M/XDR-TB.
Our ﬁndings are similar to previous reports suggesting that
surgical resection may improve M/XDR-TB outcomes.15,23,24 Also,
the WHO recommends surgery be considered for the management
of M/XDR-TB patients failing therapy and with a localized lesion,
emphasizing surgical expertise and experience. Thus our ﬁndings
support the important role of adjunctive surgical resection in the
management of pulmonary M/XDR-TB patients who meet the
criteria for surgery. The role of early culture conversion in
predicting treatment outcomes has been suggested.25 However
our study is the ﬁrst to demonstrate that a lack of culture
conversion by 4 months is a predictor of poor treatment outcome,
an outcome that highlights the importance of monitoring M/XDR-
TB patients based on regular culture results. Further studies are
needed to validate the use of the sputum 4-month culture
conversion as a predictor of poor treatment outcome, which may
be analogous to the use of 2-month culture conversion to assess
the risk of relapse among drug-susceptible patients.22
There are a few limitations to our study. First, given that this is
the ﬁrst cohort of patients to ever receive treatment for M/XDR-TB
in Georgia through the Georgian NTP, we suspect that many
retreatment cases had undergone multiple courses of treatment
for TB, but the exact number of prior courses of therapy among
retreatment cases was not known. Second, although it was the
policy to perform monthly sputum cultures, 38 (10%) patients
missed more than two cultures.
The ﬁndings from our study have several implications for TB
control activities in Georgia. First, given newly diagnosed cases had
a more favorable treatment outcome, special attention is needed to
detect M/XDR-TB cases early. To help enhance MDR-TB case
detection, the use of a rapid molecular diagnostic test, a line probe
assay called MTBDRplus, has been implemented in Georgia.26
Second, one of the independent risk factors for a poor treatment
outcome was the presence of XDR-TB. It is crucial to strengthen
activities for effective use and control of SLDs to prevent the
further emergence of XDR-TB. This includes advocacy and public
education in order to gain support for health policy changes to
limit access to key SLDs, which are currently readily available
through Georgian pharmacies without a prescription, in an effort
to reduce the further emergence of M/XDR-TB.
In conclusion, there was a rapid scale-up of M/XDR-TB
treatment in Georgia beginning in 2008. In multivariable analyses,
independent risk factors for a poor treatment outcome included
prior treatment, the presence of XDR-TB, BMI 18.5, and bilateral
inﬁltrates on chest radiograph. Sputum culture conversion by 4
months and adjunctive surgery for pulmonary TB were indepen-
dent factors associated with a favorable outcome. Additional
investigations are needed to further deﬁne the role of surgery inthe treatment of M/XDR-TB and to validate the use of the 4-month
culture conversion as a predictor of a successful treatment
outcome among patients with highly drug-resistant TB.
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